COMP <GO>
FENC vs TRXB // PIOTROSKI F-SCORE QUALITY
Fennec Pharmaceuticals Inc. (NASDAQ) VS. TRex Bio Inc. (NASDAQ) • 15-METRIC TALLY: FENC 1
— TRXB 1
■ METRIC PARITY
LAST: $10.95 (+0.74%) • MKT CAP: $383.6M
piotroski-score
2/9
LAST: $13.52 (-6.31%) • MKT CAP: $371.1M
piotroski-score
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (FENC VS. TRXB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | FENC | TRXB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -25.90% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.25% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -14.10% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -6.10% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.31 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 2/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.5 | 48.3 | -2.81 | TRXB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $383.6M | $371.1M | $12.6M | FENC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | FENC REV | TRXB REV | FENC GROSS % | TRXB GROSS % | FENC FCF | TRXB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $44.6M | — | — | — | -$12.5M | — |
| FY 2024 | $47.5M | — | — | — | $27.0M | — |
| FY 2023 | $21.3M | — | — | — | -$17.1M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
FENC // BETA —
TRXB // BETA —